Nelson B. Moseley Ii

Array ( [id] => 16991873 [patent_doc_number] => 20210230293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => ANTI-CD73 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/138279 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900814 [patent_doc_number] => 20210179730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 [patent_app_type] => utility [patent_app_number] => 17/138403 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16776632 [patent_doc_number] => 20210113709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Glycan-dependent Immunotherapeutic Molecules [patent_app_type] => utility [patent_app_number] => 17/134828 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052252 [patent_doc_number] => 20210261686 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/135170 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17022357 [patent_doc_number] => 20210246228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => FC-REGION VARIANTS WITH MODIFIED FCRN- AND PROTEIN A-BINDING PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/126838 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32729 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900800 [patent_doc_number] => 20210179716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => Antibodies Specific for CD47, PD-L1, and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/120935 [patent_app_country] => US [patent_app_date] => 2020-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17120935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18837736 [patent_doc_number] => 11845799 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Anti-Ly6G6D antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/119753 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 107 [patent_figures_cnt] => 132 [patent_no_of_words] => 58565 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17119753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878039 [patent_doc_number] => 11028172 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-06-08 [patent_title] => Anti-TIGIT antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 17/117969 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 13993 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20466632 [patent_doc_number] => 12522665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Methods and systems for treating or preventing pregnancy-related hypertensive disorders [patent_app_type] => utility [patent_app_number] => 17/783783 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 18725 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709239 [patent_doc_number] => 20230331852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 17/779428 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17779428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593142 [patent_doc_number] => 12150960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-26 [patent_title] => Modified cell expansion and uses thereof [patent_app_type] => utility [patent_app_number] => 17/108076 [patent_app_country] => US [patent_app_date] => 2020-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 89 [patent_no_of_words] => 45798 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822710 [patent_doc_number] => 20210138003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => NOVEL STRAINS HAVING EFFECTS OF PREVENTING OR TREATING CANCERS [patent_app_type] => utility [patent_app_number] => 17/096031 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082104 [patent_doc_number] => 20210277110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/090961 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80415 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17090961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056531 [patent_doc_number] => 20220387617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => USE OF CD200 PROTEIN AND CD200 FUSION PROTEIN IN PREPARING A DRUG FOR TREATING PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/761538 [patent_app_country] => US [patent_app_date] => 2020-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612201 [patent_doc_number] => 20210030854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST RENAL CELL CARCINOMA (RCC) AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/072528 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42941 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839513 [patent_doc_number] => 20210147525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING PATHOGENIC BLOOD VESSEL DISORDERS [patent_app_type] => utility [patent_app_number] => 17/072952 [patent_app_country] => US [patent_app_date] => 2020-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17072952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19076525 [patent_doc_number] => 11945875 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-02 [patent_title] => Motile sperm domain containing protein 2 and cancer [patent_app_type] => utility [patent_app_number] => 17/068959 [patent_app_country] => US [patent_app_date] => 2020-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 62 [patent_no_of_words] => 30956 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762400 [patent_doc_number] => 20210107981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => ANTI-PD-1 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-PD-1 ANTIBODIES AND METHODS OF USING ANTI-PD-1 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/068477 [patent_app_country] => US [patent_app_date] => 2020-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17068477 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20414191 [patent_doc_number] => 12497461 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Human NTCP-binding antibody capable of inhibiting infection of hepatitis B virus (HBV) to human hepatocytes [patent_app_type] => utility [patent_app_number] => 17/766789 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 22 [patent_no_of_words] => 12723 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18005010 [patent_doc_number] => 20220363776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OVARIAN CANCER, BREAST CANCER OR PANCREATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/754403 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754403 [rel_patent_id] =>[rel_patent_doc_number] =>)